Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $171M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| - | Apple Tree... | appletreep... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.08.2020 | - | $106M | - |
| 22.08.2019 | Series A | $65M | - |
Mentions in press and media 18
| Date | Title | Description |
| 15.05.2025 | Vivo Capital: Public Fund Closed With Over $740 Million In Commitments | Vivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund... |
| 01.05.2025 | Швейцарская Novartis купит производителя лекарств от заболеваний почек Regulus за $1,7 млрд | Согласно условиям сделки, Novartis выплатит $7 за акцию наличными авансом, или около $800 млн, и еще $7 за акцию акционерам Regulus, если основной кандидат на лекарственный препарат, Фарабурсен, получит одобрение регулирующих органов, сообщ... |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M. The round added Frazier Life Sc... |
| 04.10.2024 | Frazier Life Sciences: Over $630 Million Added To Evergreen Public Fund | Frazier Life Sciences (FLS), a healthcare investment firm focused on innovative therapeutics, announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscri... |
| 24.08.2024 | The Rise of RNA Medicines: Borealis Biosciences and the Future of Kidney Disease Treatment | In the world of biotechnology, innovation is the lifeblood. Borealis Biosciences has emerged as a beacon of hope in the treatment of kidney diseases. Recently, the company raised $150 million in Series A financing, marking a significant mil... |
| 22.08.2024 | Borealis Biosciences: RNA Medicines Company Raises $150 Million (Series A) | Borealis Biosciences, a next-generation RNA medicines company, has emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis, and committed strategic research collaboration fu... |
| 08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options. Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors WOODBUR... |
| 12.06.2023 | Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG | Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion |
| 12.06.2023 | Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG | Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion Chinook’s diversified p... |
Show more